Physician profile
Edward F Good
NPI 1376589903
$4,713.13
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,928 · 2020: $755 · 2021: $1,852 · 2022: $114 · 2023: $47.15 · 2024: $16.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $745.46 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $391.92 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $384.07 | 2019-2020 | |
| Abbvie INC. | $373.12 | 2019-2024 | |
| Amarin Pharma, INC. | $340.82 | 2019-2021 | |
| Pfizer INC. | $294.56 | 2019-2022 | |
| Novo Nordisk INC | $281.77 | 2019-2022 | |
| Astellas Pharma US INC | $237.04 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $182.83 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $168.30 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $125.71 | 2021 | |
| Lilly USA, LLC | $125.46 | 2020-2021 | |
| Daiichi Sankyo INC. | $119.81 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $119.02 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $111.05 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $96.12 | 2021-2023 | Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $80.05 | 2021 | |
| Esperion Therapeutics, INC. | $75.46 | 2021 | |
| Sunovion Pharmaceuticals INC. | $56.98 | 2021 | |
| Allergan, INC. | $49.47 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $45.78 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $45.48 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $42.16 | 2019-2021 | |
| Horizon Therapeutics Plc | $40.35 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.08 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.49 | 2021-2022 | |
| Dexcom, INC. | $21.59 | 2021 | |
| Genentech USA, INC. | $21.14 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.71 | 2019 | |
| Eisai INC. | $16.53 | 2021 | |
| Biogen, INC. | $13.76 | 2021 | |
| Medtronic, INC. | $12.97 | 2021 | |
| Welch Allyn | $12.78 | 2020 | |
| Shire North American Group INC | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Good listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.